NEW YORK, Sept. 9, 2015 /PRNewswire/ -- Dementia refers to a group of mental disorders that causes progressive decline in the intellectual functioning of a person.
The precise cause of dementia is unknown and it depends upon the type of mental disorder a person is suffering from. Dementia is one of the major causes of disability among the elderly population.
In addition, with the rise in aging population, the proportion of patients with neurodegenerative diseases is also surging. The treatment of movement disorder and dementia depends upon the cause of the disease.
It is treated symptomatically with the help of biological therapy and medications such as small molecules.
In addition, awareness about mental diseases has risen in various parts of the world owing to growing investments and initiatives undertaken by private and public health institutions.
Increasing prevalence of neurodegenerative disorders, rising awareness about mental diseases, and growing R&D investments in drug discovery and developments are the key driving factors of the treatment for syndromes of dementia and movement disorders market.
On the other hand, strict regulatory requirement and long approval time for drugs, and lack of comprehensive therapeutic management of dementia and movement disorders are major concerns for the market.
In addition, most of the drugs fail in Phase III due to lack of sufficient knowledge about the mechanisms of the brain and the unknown causes of the disease. Rising number of collaborations and partnerships is the major trend in the market leading to rise in discovery and development of dementia and movement disorder drugs.
North America dominates the global market for treatment for syndromes of dementia and movement disorders due to large number of aging population and increasing incidence of neurodegenerative diseases.
Asia is expected to show high growth rates in the next five years in the global treatment for syndromes of dementia and movement disorders market.
Some of the key driving forces for treatment for syndromes of dementia and movement disorders market in emerging countries are increasing geriatric population, large pool of patients and rising awareness of mental disorders. In addition, various initiative programs are organized to improve the status of awareness about dementia and movement disorders.
This report provides in-depth analysis and estimation of the treatment for syndromes of dementia and movement disorders market for the period 2014 to 2020, considering 2013 as the base year for calculation.
In addition, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report.
The treatment for syndromes of dementia and movement disorders market is categorized on the basis of the drugs used to treat progressive dementia, drugs used to treat progressive dementia with neurological abnormalities, drugs used to treat movement disorder syndromes, and geography.
Based on drugs used to treat progressive dementia, progressive dementia with neurological abnormalities and movement disorder syndromes the market comprises of disease based therapeutics and drug category.
On the basis of geography, the report identifies and analyses the market size and predictions for North America, Europe, Asia, and Rest of the World (RoW).
Some of the major players in the treatment for syndromes of dementia and movement disorders market are F. Hoffmann-La Roche, Ltd., Novartis AG, Merck & Co., Inc., Sanofi S.A., Valeant Pharmaceutical International, Inc., AstraZeneca GmbH and Pfizer, Inc.
These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.
Read the full report: http://www.reportlinker.com/p03175821-summary/view-report.html
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.